SCHEMBL1607002

SCHEMBL1607002

O=C(Nc1nccs1)c1cccn1Cc1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
HPGD P15428 4/20 0.64
ALDH1A1 P00352 4/20 0.64
NPSR1 Q6W5P4 2/20 0.64
MAPK1 P28482 2/20 0.64
TSHR P16473 1/20 0.64
RECQL P46063 1/20 0.64
HSD17B10 Q99714 1/20 0.64
SCN3A Q9NY46 4/20 0.61
SCN5A Q14524 1/20 0.61
SCN9A Q15858 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
CNR2 P34972 6/20 0.58
CNR1 P21554 2/20 0.58
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MGAM O43451 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1607522 0.91 SCN3A (0.71) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL24434940 0.89 SCN3A (0.61) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL30555384 0.87 HPGD (0.55) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL7081342 0.79 CNR2 (0.48) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL1605893 0.78 ALDH1A1 (0.58) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL1607238 0.78 SMN1; SMN2 (0.67) MEN1KMT2AHPGDALDH1A1MAPK1
SCHEMBL1606140 0.77 CNR2 (0.53) ALDH1A1CNR2CNR1RAB9AKDM4E
SCHEMBL2655012 0.76 CNR2 (0.53) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL1607222 0.76 MEN1 (0.62) MEN1KMT2AHPGDALDH1A1NPSR1
SCHEMBL9072224 0.74 MEN1 (0.55) MEN1KMT2AHPGDALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148413-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2012-04-03 US disclosed
US-8148413-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2012-04-03 US disclosed
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES TRANSTECH PHARMA, INC. (US) 2011-04-07 US disclosed
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES TRANSTECH PHARMA, INC. (US) 2011-04-07 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-7812043-B2 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes TRANSTECH PHARMA, INC. (US) 2010-10-12 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes NOVO NORDISK A/S (DK) 2007-02-01 US disclosed
EP-1689392-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES NOVO NORDISK A/S (DK) 2006-08-16 EP disclosed
WO-2005049019-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES NOVO NORDISK A/S (DK) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027140-A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes GALK1, GCKR, GCK MEN1 4335/4885KMT2A 3033/4885HPGD 637/4885
US-20110082144-A1 N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES GCKR, GCK, GALK1 MEN1 3174/4885KMT2A 1570/4885HPGD 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.